rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia (Q39473725)
Jump to navigation
Jump to search
scientific article published on 14 September 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia |
scientific article published on 14 September 2011 |
Statements
1 reference
rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia (English)
1 reference
1 reference
Xiaowen Ge
1 reference
Lin Wu
1 reference
Stacey Fernandes
1 reference
Chun Wang
1 reference
Xu Li
1 reference
Jennifer R Brown
1 reference
Xuebin Qin
1 reference
14 September 2011
1 reference
1 reference
17
1 reference
21
1 reference
6702-6711
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference